Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lung Neoplasms 2Glioma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Ependymoma 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 9mogamulizumab 6Biopsy 6fludarabine 5fludarabine phosphate 4Specimen Handling 4Immunoglobulin G 4Disulfides 4Brentuximab Vedotin 4ruxolitinib 3romidepsin 3pembrolizumab 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Etoposide 3Busulfan 3hypericin 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Nivolumab 2Melphalan 2Depsipeptides 2tofacitinib 1thymoglobulin 1tazemetostat 1talimogene laherparepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Cutaneous × Pharmacogenomic Variants × 1 year × Clear all
NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡